1 Einträge von mit rare rhophylac
www.cslbehring.ch
Datum der Indexierung 04.10.2024 23:30:14
erkannte Namen Ria STAP | Norbert Heimberger | Asia Pacific |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring more | first your | plasma plant | with award | approved approval | patients bern | treatment switzerland | factor immunglobulin | company rare | market production |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
rare and serious diseases and to provide therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D CSL R&D in Switzerland Investigator Initiated Stu Rhophylac® for ITP in the U.S. The U.S. Food and Drug Administration approves the treatment of immune thrombocytopenic purpura (ITP) as an additional indication for Rhophylac®. 2007 FDA approval for Privigen® The U.S. Food and Dru
Text Inhalt Text aus URL
Log Metriken 86083
erkannte Namen Ria STAP | Norbert Heimberger | Asia Pacific |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring more | first your | plasma plant | with award | approved approval | patients bern | treatment switzerland | factor immunglobulin | company rare | market production |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
rare and serious diseases and to provide therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D CSL R&D in Switzerland Investigator Initiated Stu Rhophylac® for ITP in the U.S. The U.S. Food and Drug Administration approves the treatment of immune thrombocytopenic purpura (ITP) as an additional indication for Rhophylac®. 2007 FDA approval for Privigen® The U.S. Food and Dru
Text Inhalt Text aus URL
Log Metriken 86083